Ashraf Malhas, PhD,  —

Approval of Sickle Cell Disease Bill by Senate Committee Welcomed by Emmaus Life Sciences

A U.S. Senate committee unanimously supported the Sickle Cell Disease Act of 2018, and Emmaus Life Sciences is also announcing its support of the bill. The Sickle Cell Disease Research, Surveillance, Prevention and Treatment Act of 2018 (S. 2465) seeks to improve the understanding of the healthcare system regarding sickle…

Increasing Doses of Hydroxyurea Benefits Young Sickle Cell Patients

Researchers have found that a new dosing regimen of the drug hydroxyurea results in levels of fetal hemoglobin above 20 percent in sickle cell anemia patients, and reduces hospitalizations by at least two-fold. Hydroxyurea has been shown to be of clinical benefit to children with sickle cell anemia (SCA) and is…